In 458 patients with high-risk locally advanced rectal cancer, total neoadjuvant therapy (capecitabine plus oxaliplatin with long-course radiotherapy) improved 3-year DFS vs chemoradiotherapy (74.8% v 66.0%; HR 0.674), with more grade ≥3 neoadjuvant toxicity (27.6% v 8.6%).
RCTn = 458
Wang et al. Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial